Research and development, capital investment and certification in new fields
First written in FY2016. 23 of 34 entries say "Restated". Latest entry: 2026-11-11.
63 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「R&D expenses for the fiscal year were ¥584 million, up 8.0% year on year.」
R&D expenses increased from ¥541 million in the previous fiscal year to ¥584 million, and the company continues to expand R&D in food and beverages, medical applications, P-Bas, new materials, aerospace and other areas. - 2026-05-11MitigatedRevision to earnings forecasts
「In the domestic business during the fourth quarter, orders began recovering more than previously anticipated, resulting in an improvement in the cost ratio,」
国内事業について、前回公表時の想定を上回る受注回復と原価率改善を記載した。前回までの減収・体制整備の遅れに関する記載に対し、改善方向の変化を示しているが、業績予想に基づく説明である。 - FY2025-H1RestatedAnnual report
「The amount spent on R&D activities by our group as a whole during the current interim consolidated accounting period was ¥271 million. There were no material changes in the status of our group's R&D activities during the current interim consolidated accounting period.」
The company continues its R&D activities in new fields and new technologies, but there have been no material changes in the status of these activities. - FY2024Lower R&D expenses; continued development of new technologiesAnnual report
「The company aims to expand business with industries less affected by economic fluctuations and expected to grow in the future, specifically the food and beverage and medical sectors. It will also apply the technologies it has developed through the manufacture of mold components and FA components and equipment to existing and new businesses, including metal component processing, the development of new materials using its P-Bas metal integration technology, and initiatives in the aerospace industry, which is expected to achieve further growth.」
The company continues its initiatives in food and beverages, medical applications, new materials using P-Bas, and aerospace. R&D expenses were ¥507 million, down 7.2% year on year. - FY2024-Q3RestatedAnnual report
「The amount spent on research and development activities across the group during the third quarter of the current consolidated cumulative period was ¥386 million. There were no material changes in the status of the group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company continues its R&D activities and reported an amount of ¥386 million for the cumulative third quarter. It stated that there had been no material changes in the status of these activities. - FY2024-Q1RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the cumulative first quarter was ¥134 million. There were no material changes in the status of the group’s R&D activities during the cumulative first quarter.」
The company continues its R&D activities and disclosed R&D expenses of ¥134 million for the cumulative quarter. It stated that there had been no material changes in the status of these activities. - FY2023AdvancedAnnual report
「The company is particularly focused on aerospace-related applications requiring ultra-precision machining and entered into a technology partnership agreement in May 2023 with Dymon Co., Ltd., which is pursuing the world's first private-sector lunar exploration mission.」
In aerospace-related R&D, the company entered into a technology partnership agreement with 株式会社ダイモン in May 2023. R&D expenses were ¥546 million, up 7.4% year on year. - FY2023-Q3RestatedAnnual report
「The amount spent on research and development activities across the group during the third quarter of the current consolidated cumulative period was ¥415 million. There were no material changes in the status of the group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company recorded R&D expenses of ¥415 million and stated that there had been no material changes in the status of its R&D activities. - FY2023-Q2RestatedAnnual report
「The amount spent on research and development activities by the group as a whole during the cumulative second quarter of the current consolidated fiscal year was ¥267 million.」
The company continues its R&D activities and reported R&D expenses of ¥267 million for the cumulative second quarter of the fiscal year. It stated that there had been no material changes in the status of these activities. - FY2023-Q1RestatedAnnual report
「The amount spent on research and development activities by the group as a whole during the cumulative first quarter of the current consolidated fiscal year was ¥130 million. There were no material changes in the status of the group's research and development activities during the cumulative first quarter of the current consolidated fiscal year.」
The company continued its research and development activities and reported spending of ¥130 million for the cumulative first quarter. It stated that there were no material changes in the status of these activities. - FY2022AdvancedAnnual report
「The company is applying to register a trademark for P-Bas, a technology meaning punch bonding and sintering. It aims to further develop the Punch Group by working in aerospace-related fields, where ultra-precision machining is required, to improve its technological capabilities and through other initiatives.」
Regarding research and development, the company specified its efforts involving the new P-Bas technology and aerospace-related fields. Research and development expenses also increased 3.8% from the previous fiscal year to ¥508 million. - FY2022-Q3RestatedAnnual report
「The amount spent on research and development activities across the group during the third quarter of the current consolidated cumulative period was ¥364 million. There were no material changes in the status of the group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company recorded research and development expenses of ¥364 million, while stating that there were no material changes in the status of its research and development activities. - FY2022-Q2RestatedAnnual report
「The amount spent on research and development activities by the group as a whole during the cumulative second quarter of the current consolidated fiscal year was ¥238 million. There were no material changes in the status of the group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
The company reported research and development spending of ¥238 million, while stating that there were no material changes in the status of these activities. - FY2022-Q1RestatedAnnual report
「The amount spent on research and development activities across the group during the first quarter of the current consolidated cumulative period was ¥117 million. There were no material changes in the status of the group's research and development activities during the first quarter of the current consolidated cumulative period.」
The company continued its research and development activities and reported spending of ¥117 million for the cumulative first quarter, while stating that there were no material changes in the status of these activities. - FY2021-Q3RestatedAnnual report
「The amount spent on research and development activities by the group as a whole during the cumulative third quarter of the current consolidated fiscal year was ¥362 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
The company continued its research and development activities and reported spending of ¥362 million for the cumulative third quarter of the consolidated fiscal year, while stating that there were no material changes in the status of these activities. - FY2021-Q1RestatedAnnual report
「The amount spent on research and development activities by the group as a whole during the cumulative first quarter of the current consolidated fiscal year was ¥121 million. There were no material changes in the status of the group's research and development activities during the cumulative first quarter of the current consolidated fiscal year.」
The company continued its research and development activities and reported spending of ¥121 million for the cumulative first quarter. It stated that there were no material changes in the status of these activities. - FY2020-Q3RestatedAnnual report
「The amount spent on research and development activities by the group as a whole during the cumulative third quarter of the current consolidated fiscal year was ¥334 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
The company recorded research and development expenses of ¥334 million, while stating that there were no material changes in the status of its research and development activities. - FY2020-Q2RestatedAnnual report
「The amount spent on research and development activities across the group during the second quarter of the current consolidated cumulative period was ¥218 million. There were no material changes in the status of the group's research and development activities during the second quarter of the current consolidated cumulative period.」
The company continued its research and development activities and reported spending of ¥218 million for the cumulative second quarter of the consolidated fiscal year. It stated that there were no material changes in the status of these activities. - FY2020-Q1RestatedAnnual report
「The amount spent on research and development activities across the group during the first quarter of the current consolidated cumulative period was ¥107 million. There were no material changes in the status of the group's research and development activities during the first quarter of the current consolidated cumulative period.」
The company recorded research and development expenses of ¥107 million and stated that there were no material changes in its research and development activities. - FY2019AdvancedAnnual report
「The company aims to expand business with industries less susceptible to economic fluctuations and expected to grow in the future, specifically the food and beverage and medical sectors. It is also investing, from a medium- to long-term perspective, in areas such as aerospace through certification and other initiatives. Research and development expenses for the consolidated fiscal year were ¥443 million, up 20.7% from the previous fiscal year.」
The company continued its initiatives in the food and beverage, medical and aerospace-related fields, and research and development expenses increased to ¥443 million, up 20.7% from the previous fiscal year. - FY2019-Q3RestatedAnnual report
「The amount spent on research and development activities across the group during the third quarter of the current consolidated cumulative period was ¥313 million. There were no material changes in the status of the group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company reported research and development spending of ¥313 million, while stating that there were no material changes in the status of these activities. - FY2019-Q2RestatedAnnual report
「The amount spent on research and development activities across the group during the second quarter of the current consolidated cumulative period was ¥200 million. There were no material changes in the status of the group's research and development activities during the second quarter of the current consolidated cumulative period.」
The company continued its research and development activities and reported spending of ¥200 million for the cumulative second quarter of the consolidated fiscal year. It stated that there were no material changes in the status of these activities. - FY2019-Q1RestatedAnnual report
「The amount spent on research and development activities across the group during the first quarter of the current consolidated cumulative period was ¥97 million. There were no material changes in the status of the group's research and development activities during the first quarter of the current consolidated cumulative period.」
The company continued its research and development activities and reported spending of ¥97 million for the cumulative first quarter of the consolidated fiscal year. It stated that there were no material changes in the status of these activities. - FY2018AdvancedAnnual report
「In its priority areas, the company aims to expand business with industries less susceptible to economic fluctuations and expected to grow in the future, specifically the food and beverage and medical sectors. It is also investing, from a medium- to long-term perspective, in areas such as aerospace through certification and other initiatives. Research and development expenses for the consolidated fiscal year were ¥367 million, up 13.6% from the previous fiscal year.」
The company specified its investment areas as food and beverages, medical care and aerospace-related fields, and research and development expenses increased to ¥367 million, up 13.6% from the previous fiscal year. - FY2018-Q3RestatedAnnual report
「The amount spent on research and development activities across the group during the third quarter of the current consolidated cumulative period was ¥272 million. There were no material changes in the status of the group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company continued its research and development activities and reported spending of ¥272 million for the cumulative third quarter of the consolidated fiscal year. It stated that there were no material changes in the status of these activities. - FY2018-Q2RestatedAnnual report
「The amount spent on research and development activities across the group during the second quarter of the current consolidated cumulative period was ¥179 million. There were no material changes in the status of the group's research and development activities during the second quarter of the current consolidated cumulative period.」
The company continued its research and development activities and reported spending of ¥179 million for the cumulative second quarter of the consolidated fiscal year. It stated that there were no material changes in the status of these activities. - FY2018-Q1RestatedAnnual report
「The amount spent on research and development activities across the group during the first quarter of the current consolidated cumulative period was ¥84 million. There were no material changes in the status of the group's research and development activities during the first quarter of the current consolidated cumulative period.」
The company continued its research and development activities and reported spending of ¥84 million for the cumulative first quarter. It stated that there were no material changes in the status of these activities. - FY2017RestatedAnnual report
「Research and development expenses for the current consolidated fiscal year were ¥323 million. To further expand globally the group's long-standing commitment to manufacturing, the company is actively entering new business areas and making focused investments in growth areas to improve profitability and efficiency.」
The company recorded research and development expenses of ¥323 million and continued to enter new business areas and make focused investments in growth areas. - FY2017-Q3RestatedAnnual report
「The amount spent on research and development activities across the group during the third quarter of the current consolidated cumulative period was ¥236 million. There were no material changes in the status of the group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company continued its research and development activities and reported spending of ¥236 million for the cumulative third quarter of the consolidated fiscal year. It stated that there were no material changes in the status of these activities. - FY2017-Q2RestatedAnnual report
「The amount spent on research and development activities by the group as a whole during the cumulative second quarter of the current consolidated fiscal year was ¥156 million.」
The company continued its research and development investment and reported spending of ¥156 million for the cumulative second quarter of the consolidated fiscal year. - FY2016First statedAnnual report
「The Group will promote R&D investment, capital investment, and the acquisition of various certifications to expand transactions in new fields that are less affected by economic fluctuations and are expected to grow in the future.」
The company says it will pursue research and development investment, capital investment and certification in new fields less susceptible to economic fluctuations.